KEYNOTE‑119: Phase 3 Study of Pembrolizumab versus Single-Agent Chemotherapy for Metastatic Triple-Negative Breast Cancer (mTNBC) - Cortes, J; Lipatov, O; Im, S A (Ann Oncol, 2019)
. doi:810.1093/annonc/mdz1394